Research programme:antibody-drug conjugates - 9Bio Therapeutics/National Research Council Canada
Latest Information Update: 31 Mar 2025
At a glance
- Originator 9Bio Therapeutics
- Developer 9Bio Therapeutics; National Research Council Canada
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer; Head and neck cancer